Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have earned an average recommendation of “Moderate Buy” from the five research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $43.60.

Several research firms have issued reports on COLL. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Friday, January 10th. Piper Sandler decreased their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, January 10th.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $30.95 on Friday. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical has a 1 year low of $28.39 and a 1 year high of $42.29. The company has a market capitalization of $998.14 million, a PE ratio of 13.34 and a beta of 0.82. The company has a fifty day moving average of $31.03 and a two-hundred day moving average of $34.14.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of the stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the transaction, the executive vice president now directly owns 119,184 shares of the company’s stock, valued at $3,937,839.36. This represents a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 3.98% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its holdings in Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after purchasing an additional 175,892 shares in the last quarter. Penserra Capital Management LLC purchased a new position in Collegium Pharmaceutical during the third quarter worth about $757,000. Barclays PLC raised its holdings in Collegium Pharmaceutical by 152.2% during the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock worth $2,899,000 after purchasing an additional 45,291 shares in the last quarter. Sanctuary Advisors LLC raised its holdings in Collegium Pharmaceutical by 10.7% during the third quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company’s stock worth $695,000 after purchasing an additional 1,731 shares in the last quarter. Finally, FMR LLC raised its holdings in Collegium Pharmaceutical by 1,532.2% during the third quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock worth $1,459,000 after purchasing an additional 35,439 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.